Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced Cutaneous Squamous Cell Carcinoma
Results of the second interim analysis of the KEYNOTE-629 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With Pembrolizumab
The results of a phase II study in patients with recurrent mismatch repair deficient and/or microsatellite instability-high endometrial cancer
FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease
Evidence for efficacy is based on the results from KD025-213 study
Hypogammaglobulinemia and Sars-CoV-2 Viraemia Determine COVID-19 Severity in Patients with Haematological Malignancies
Coronavirus infection itself, rather than cytokine storm, lead to severe and lethal COVID-19 in patients with haematological malignancies
Combined MRI-directed and Standard Biopsy in Men With Elevated PSA and Positive Results on MRI Non-inferior to Standard Biopsy
Findings from the STHLM3-MRI population-based prostate cancer screening study by invitation
FDA Approves Daratumumab and Hyaluronidase-fihj With Pomalidomide and Dexamethasone for Multiple Myeloma
Evidence for efficacy is based on the results from the APOLLO study
FDA Approves Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn for Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma
Evidence for efficacy is based on the results from the Study JZP458-201
FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or Metastatic Urothelial Cancer
Evidence is based on the results from the EV-301 study that was required to confirm the clinical benefit of the 2019 accelerated approval
Analysis of the Gut Microbiome Provides Clues to Survival Following Nivolumab Therapy for Advanced Gastric Cancer
Findings from the observational/translational DELIVER study
EMA Recommends Granting a Conditional Marketing Authorisation for Tafasitamab
It is intended for the treatment of relapsed or refractory diffuse large B‑cell lymphoma not eligible for autologous stem-cell transplant
Adding Avelumab to Preoperative Chemoradiotherapy Provides Promising Anti-Tumour Activity in Locally Advanced Rectal Cancer
Findings from the AVANA study
Expression of AR-regulated Genes in CTCs Is Prognostic for Survival and Radiographic Progression in Metastatic Prostate Cancer
Transcriptional profile detectable in circulating tumour cells could serve as an independent prognostic marker beyond androgen receptor splice variant 7